Erlotinib Impurity 45 | CAS 591-19-5 - Request Quote
Erlotinib Impurity 45
| SZ CAT No: | SZ-E018071 |
| CAS No | 591-19-5 |
| Mol.F. | C6H6BrN |
| Mol.Wt. | 172.0 |
| Inv. Status | Synthesis on demand |
| Rel. CAS No | 56967-17-0 (HCl salt) |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Erlotinib Impurity 45 is chemically 3-Bromoaniline. Erlotinib Impurity 45 is supplied with detailed characterization data compliant with regulatory guideline. Erlotinib Impurity 45 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Erlotinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 591-19-5
Purchase 591-19-5
Order 591-19-5
Enquire 591-19-5
price of 591-19-5
591-19-5 Supplier
591-19-5 Manufacturer
591-19-5 Exporter
buy high quality Erlotinib Impurity 45
Purchase Erlotinib Impurity 45
Erlotinib Impurity 45 suppliers
Erlotinib Impurity 45 manufacturers
Erlotinib Impurity 45 price
Order Erlotinib Impurity 45
Enquire Erlotinib Impurity 45
Erlotinib Impurity 45 cost
Erlotinib Impurity 45 Supplier
Erlotinib Impurity 45 Distributor
Erlotinib Impurity 45 for Method Validation
Erlotinib Reference Standard
Erlotinib Impurity 45 for ANDA Filing
Erlotinib Impurity 45 for Forced Degradation Studies
Erlotinib Impurity 45 Identification Standards
Erlotinib Impurity 45 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.